[Pharmacotherapy for obesity]

Area of Science:

• Medical Science
• Pharmacology
• Obesity Research

Background:

• Obesity is a complex chronic condition requiring multifaceted management strategies.
• Lifestyle modifications (diet, exercise) are the first line of treatment for obesity.
• Pharmacotherapy is considered when lifestyle changes are insufficient to achieve significant weight loss.

Purpose of the Study:

• To outline the indications and considerations for pharmacotherapy in obesity management.
• To provide guidance on selecting appropriate anti-obesity medications.
• To establish criteria for treatment efficacy and discontinuation.

Main Methods:

• Review of current guidelines and evidence for obesity pharmacotherapy.
• Identification of patient criteria for initiating pharmacotherapy (BMI thresholds, comorbidities).
• Listing of available pharmacotherapeutic agents (liraglutide, orlistat) and their dosages.

Main Results:

• Pharmacotherapy is indicated for individuals with a BMI > 30 kg/m² or BMI > 27 kg/m² with comorbidities like Type 2 diabetes.
• Liraglutide (3 mg) and orlistat (120 mg/60 mg) are key pharmacotherapeutic options.
• Treatment selection depends on patient factors, clinical status, side effects, and cost.

Conclusions:

• Pharmacotherapy offers a viable option for sustained weight management in obesity.
• A minimum weight loss of 5% within 12 weeks is a benchmark for treatment continuation.
• Discontinuation of pharmacotherapy is recommended if the 5% weight loss goal is not met.